RE: RNS published!1 Apr 2021 17:30
xercise of Warrants, Issue of Equity& Total Voting Rights
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that it has received a warrant exercise notice from HT Riverwood Multi-Growth Fund ("Riverwood"), a fund managed by Atlantis Investment Management Limited ("Atlantis") in respect of 2,272,727 new ordinary shares of 0.2 pence in the Company ("New Ordinary Shares"), with an exercise price of 22 pence per share. Proceeds of £500,000 have been received by the Company in respect of the warrant exercise.
Once issued, the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Application has been made for the 2,272,727 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 7 April 2021.